Jeil Pharma Holdings (XKRX:002620) Net Income From Continuing Operations : ₩-33,084 Mil (TTM As of Mar. 2024)

View and export this data going back to 1988. Start your Free Trial

What is Jeil Pharma Holdings Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Jeil Pharma Holdings's net income from continuing operations for the three months ended in Mar. 2024 was ₩-1,761 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-33,084 Mil.

Jeil Pharma Holdings Net Income From Continuing Operations Historical Data

The historical data trend for Jeil Pharma Holdings's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jeil Pharma Holdings Net Income From Continuing Operations Chart

Jeil Pharma Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-95,508.84

14,941.06

-12,870.01

-83,145.01

-13,240.83

Jeil Pharma Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															18,081.98	175.33	-2,840.90	-28,657.24	-1,760.91

Jeil Pharma Holdings Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-33,084 Mil.

Jeil Pharma Holdings (XKRX:002620) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jeil Pharma Holdings Inc (XKRX:002620) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

745-5, Banpo-dong, Seocho-gu, Seoul, KOR, 137-810

Website

https://www.jeilpharm.co.kr

Jeil Pharma Holdings Inc is involved in manufacture and distribution of pharmaceutical products. The company mainly produces finished pharmaceutical products and active pharmaceutical ingredients. It has categorized its products in Antibiotic, Oncology, Cardiovascular, Gastrointestinal, Urology, Respiratory etc. The firm's manufacturing facility and research and development institute located at Yongin-si, Gyeonggi-do in Korea.

Jeil Pharma Holdings (XKRX:002620) Headlines

No Headlines